Batimastat (BB-94) is a potent matrix metalloproteinase (MMP) inhibitor that has been primarily investigated for its anti-cancer properties. It works by blocking the activity of MMP enzymes, which are involved in tumor invasion, angiogenesis, and metastasis. Due to its ability to inhibit tumor progression and spread, Batimastat has been studied in preclinical models for various cancers, including breast, lung, and glioblastoma. It has also shown potential in reducing tumor-induced angiogenesis, making it a candidate for anti-angiogenic therapy. Additionally, Batimastat has been used in research to understand the role of MMPs in disease processes beyond cancer, such as in inflammatory conditions and tissue remodeling. Despite its strong inhibitory effects, Batimastat has poor solubility and bioavailability, which limited its clinical development. However, it remains a valuable tool compound in laboratory research for studying MMP-dependent biological processes and for validating MMPs as therapeutic targets.